NCT05481827
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Enrolling by Invitation
PHASE2Ages 55+InterventionalGyroscope Therapeutics Limited
~225 participants
Updated 2024-03-22 on ClinicalTrials.gov
What's tested:GT005
At a glance
Recruiting sites
0 of 32 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence and severity of ocular and systemic adverse events (AEs)
Measured over up to Week 260
Conditions
Where it's being run
32 sites across 20 statesTexas5
Florida3
Spain3
New York2
France2
Germany2
United Kingdom2
California1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence and severity of ocular and systemic adverse events (AEs)up to Week 260
An AE is the development of an undesirable medical condition or the deterioration of a preexisting medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the IMP.